Dec 2 (Reuters) - Immunovaccine Inc IMV.TO :
* Immunovaccine's DPX-Survivac induces an immune response in diffuse large B cell Lymphoma
* Says additional study data are expected in 2016
* Early result demonstrates dpx-survivac, immunovaccine's lead cancer immune
therapy, can induce immune responses in hematologic cancers
* Source text for Eikon ID:nCCN7kqjyD
* Further company coverage IMV.TO